Theratechnologies Inc. (NASDAQ:THTX) Short Interest Update

Theratechnologies Inc. (NASDAQ:THTX) saw a significant decline in short interest in March. As of March 15th, there was short interest totalling 41,900 shares, a decline of 13.6% from the February 28th total of 48,500 shares. Based on an average daily volume of 199,200 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.2% of the shares of the company are sold short.

Analyst Upgrades and Downgrades

Separately, Research Capitl raised Theratechnologies to a “strong-buy” rating in a report on Friday, February 14th.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in THTX. Raymond James Financial Inc. purchased a new position in Theratechnologies during the fourth quarter worth about $27,000. Bank of America Corp DE boosted its position in shares of Theratechnologies by 1,416.7% during the 4th quarter. Bank of America Corp DE now owns 16,487 shares of the company’s stock valued at $30,000 after acquiring an additional 15,400 shares during the last quarter. JPMorgan Chase & Co. purchased a new position in shares of Theratechnologies during the fourth quarter worth about $33,000. BNP Paribas Financial Markets bought a new position in shares of Theratechnologies in the fourth quarter worth approximately $36,000. Finally, Virtu Financial LLC purchased a new stake in Theratechnologies in the fourth quarter valued at approximately $40,000.

Theratechnologies Trading Down 4.1 %

Shares of Theratechnologies stock opened at $1.41 on Friday. The company’s 50-day moving average price is $1.61 and its 200-day moving average price is $1.50. Theratechnologies has a 12-month low of $1.08 and a 12-month high of $2.18. The company has a market cap of $64.83 million, a price-to-earnings ratio of -14.10 and a beta of 1.11.

Theratechnologies Company Profile

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.